Boston Scientific (BSX) Financials

Boston Scientific’s latest results show continued revenue growth and stronger operating profitability, although cash liquidity weakened after substantial investment and financing activity. Q2 2026 revenue increased to $5.44 billion from $5.06 billion in Q2 2025, a 7.5% year-over-year gain. Gross profit rose 12.4% to $3.85 billion, lifting the gross margin to approximately 70.7% from 67.7%.

Operating income increased 43.8% year over year to $1.18 billion, with the operating margin expanding to 21.6% from 16.2%. Common-shareholder net income rose to $907 million from $797 million, while diluted earnings per share increased to $0.61 from $0.53. However, Q2 earnings were below Q1 2026, when common-shareholder net income was $1.34 billion and diluted EPS was $0.90.

• Consistent top-line expansion: Quarterly revenue increased from $3.17 billion in Q3 2022 to $5.44 billion in Q2 2026. Q2 2026 revenue was also 7.5% above the restated Q2 2025 level.
• Improving gross margins: Gross margin reached approximately 70.7% in Q2 2026, compared with roughly 67.7% in Q2 2025 and 66.4% in Q2 2024, indicating favorable product mix, pricing, or operating leverage.
• Operating leverage is becoming more visible: Q2 2026 operating expenses increased approximately 6.3% year over year, slower than revenue growth. As a result, operating income grew nearly 44% and the operating margin improved substantially.
• Strong operating cash generation: Cash flow from operations increased to $1.47 billion in Q2 2026 from $1.29 billion in Q2 2025. Operating cash flow has generally remained positive across the reported quarters, reaching $1.36 billion in Q4 2025 and $1.34 billion in Q3 2025.
• Higher cash generation after capital spending: Approximate operating cash flow less property and equipment purchases was $1.28 billion in Q2 2026, up from approximately $1.13 billion in Q2 2025. This provides funding for acquisitions, research and development, and debt service.
• Growing asset base and equity: Total assets increased to $45.2 billion at June 30, 2026, from $41.6 billion a year earlier. Total equity and noncontrolling interests rose to $25.2 billion from $22.7 billion over the same period, supported in part by higher retained earnings.
• Acquisition-led growth remains important: Boston Scientific spent approximately $3.4 billion on acquisitions during the first half of 2026, compared with roughly $1.0 billion in the first half of 2025. These investments may support future growth, but their success will depend on integration and returns.
• Reported results include restatements: Several 2024 and 2025 comparison periods are marked as restated in the supplied data. Investors should rely on the company’s latest filings when assessing year-over-year trends and should recognize that some historical figures may differ from previously reported results.
• Cash reserves declined sharply: Cash and equivalents fell to $539 million at the end of Q2 2026 from $1.45 billion at the end of Q1 and $1.28 billion at the end of Q3 2025. The decline followed $1.96 billion of investing cash outflows and $410 million of financing cash outflows during the quarter.
• Leverage and working-capital risks require monitoring: Total debt was approximately $12.2 billion at June 30, 2026, while inventory increased to $3.24 billion from $2.86 billion a year earlier. The current ratio fell to about 1.24 from approximately 1.37 in Q2 2025 and 1.90 in Q1 2026, leaving less short-term liquidity flexibility.

Overall, the statements point to a company with a strong multi-year growth profile, expanding margins, and robust operating cash flow. The main risks are the pace of acquisition spending, declining cash balances, rising debt exposure, and the need to convert higher inventory and acquired assets into future revenue and earnings.